Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists are used to treat diabetes, but their effects on nonalcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) remain unclear. In this study, mice with streptozotocin- and high-fat diet-induced diabetes and NASH were subcutaneously treated with liraglutide or saline (control) for 14 weeks. Glycemic control, hepatocarcinogenesis, and liver histology were compared between the groups. Fasting blood glucose levels were significantly lower in the liraglutide group than in the control group (210.0 ± 17.3 mg/dL vs. 601.8 ± 123.6 mg/dL), and fasting insulin levels were significantly increased by liraglutide (0.18 ± 0.06 ng/mL vs. 0.09 ± 0.03 ng/mL). Liraglutide completely suppressed hepatocarcinogenesis, whereas HCC was observed in all control mice (average tumor count, 5.5 ± 3.87; average tumor size, 8.1 ± 5.0 mm). Liraglutide significantly ameliorated steatosis, inflammation, and hepatocyte ballooning of non-tumorous lesions in the liver compared with the control findings, and insulin-positive β-cells were observed in the pancreas in liraglutide-treated mice but not in control mice. In conclusion, liraglutide ameliorated NASH and suppressed hepatocarcinogenesis in diabetic mice. GLP-1 receptor agonists can be used to improve the hepatic outcome of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a mouse model induced with NASH-related HCC, treatment with liraglutide (a type of GLP-1RA) was shown to prevent the progression of hepatocellular carcinoma.518 This was observed through improved glycemic control, reduced occurrence of liver cancer, and better liver histology compared to the control group.518”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [518]
In the citing paper
“In mouse models, liraglutide has been shown to completely suppress hepatocarcinogenesis.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [100]
In the citing paper
“Moreover, the long-term suppression of NASH and the favorable anti-oncogenic pathways exhibited by the GLP-1 RAs treatment could reduce the risk of de novo HCC and recurrence [100,139].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“According to epidemiological studies, increased body weight is associated with an increased risk of liver cancer and increased death rates for liver cancer [26,27].”
BackgroundNonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
AMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602 · cited 1×
“AMP-activated protein kinase inhibits the mechanistic target of rapamycin complex-1 [41].”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“Recently, studies of incretin-based therapies have focused on both their ability to improve hyperglycemia and their multiple mechanisms of action [7,8].”
BackgroundArmstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · cited 1×
“In humans, previous studies including our clinical trial demonstrated that liraglutide improved the hepatic outcome of NAFLD including serological and histological assessments along with an improvement in glycemic control [13,14].”
ResultNonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154 · cited 1×
“Nonalcoholic fatty liver disease covers a spectrum of liver diseases that range from benign simple steatosis to hepatic inflammation and fibrosis resulting from nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC) [2,3].”
BackgroundGlobal perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
Bhaskaran, K., Douglas, I., Forbes, H., dos-Santos-Silva, I., Leon, D. A., & Smeeth, L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60892-8 · Cited by 1,707 · cited 1×
“According to epidemiological studies, increased body weight is associated with an increased risk of liver cancer and increased death rates for liver cancer [26,27].”
BackgroundAMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619 · cited 1×
“AMP-activated protein kinase activation causes cell cycle arrest, which is associated with the stabilization of p53 and the cyclin-dependent kinase inhibitors p21 and p27 [39,40].”
Background
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“This pathway could represent one of the protective mechanisms against HCC development exerted by GLP-1 RAs.”
BackgroundInfluentialTong, G., Peng, T., Chen, Y., Sha, L., Dai, H., Xiang, Y., Zou, Z., He, H., & Wang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.901559 · Cited by 218
“Previous studies have shown that GLP1 receptor agonists play an important role in the occurrence and development of a variety of tumor cells (Liu et al., 2019; Kojima et al., 2020; Mao et al., 2021).”
BackgroundCurrent and emerging strategies for the prevention of hepatocellular carcinoma
Yeo, Y. H., Abdelmalek, M. F., Khan, S. A., Moylan, C. A., Rodriquez, L. M., Villanueva, A., & Yang, J. D. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01021-z · Cited by 111
“Investigations showed that GLP1 treatment was associated with a diminished risk of HCC in MASH-driven HCC mouse models 70,71 .”
Pοlyzos, S. A., Chrysavgis, L., Vachliotis, I. D., Chartampilas, E., & Cholongitas, Ε. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.010 · Cited by 97
Lin, A., Ding, Y., Li, Z., Jiang, A., Liu, Z., Wong, H. Z. H., Cheng, Q., Zhang, J., & Luo, P. (2025) · Biomarker Research · doi:10.1186/s40364-025-00765-3 · Cited by 69
“Clinical evidence further confirmed Liraglutide significantly reduces the mortality risk in patients with type 2 diabetes and concurrent prostate cancer [44].”
InfluentialArvanitakis, K., Koufakis, T., Kotsa, K., & Germanidis, G. S. (2022) · Cancers · doi:10.3390/cancers14194651 · Cited by 63
“[63] (2020) Liraglutide ameliorates NASH and suppresses HCC formation in diabetic mice Liraglutide ameliorates steatosis, inflammation, and hepatocyte ballooning of non-tumorous lesions in the liver”
BackgroundMetabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions
Leslie, J., Geh, D., Elsharkawy, A. M., Mann, D. A., & Vacca, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.029 · Cited by 61
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10192-9 · Cited by 56
Romualdo, G. R., Leroy, K., Costa, C. J. S., Bacil, G. P., Vanderborght, B., da Silva, T. C., Barbisan, L. F., Andraus, W., Devisscher, L., Câmara, N. O. S., et al. (2021) · Cancers · doi:10.3390/cancers13215583 · Cited by 58
Anti-Diabetic Therapies and Cancer: From Bench to Bedside
Kounatidis, D. C., Vallianou, N. G., Karampela, Ι., Rebelos, E., Kouveletsou, M., Dalopoulos, V., Koufopoulos, P., Diakoumopoulou, E., Tentolouris, N., & Dalamaga, Μ. (2024) · Biomolecules · doi:10.3390/biom14111479 · Cited by 52
“Both liraglutide and semaglutide showed potential in preventing disease progression and reducing tumor burden in HCC [115,116].”
Yang, C., Yao, W., Yang, C., Peng, Z., Ou, H., & Kuo, S. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13751 · Cited by 42
“This result might be explained by the pharmacological mechanisms proposed in previous in vitro and animal studies [40–50], including the direct effects of GLP-1RAs on the attenuation of hepatocyte apoptosis [41, 42], the modulation of liver Kupffer cell M1/M2 polarization [43, 44], and the…”
ResultLi, T., Lin, X., Shen, B., Zhang, W., Liu, Y., Liu, H., Wang, Y., Zheng, L., & Zhi, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1047570 · Cited by 53
“STZ-HFD treatment severely disorganized liver structures characterized by steatosis, in fl ammation, and necrosis, which were partly recovered by A. muciniphila administration (Figure 4B).”
BackgroundInfluentialMAFLD: an optimal framework for understanding liver cancer phenotypes
Crane, H., Gofton, C., Sharma, A., & George, J. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02021-7 · Cited by 51
Havranek, B., Loh, R., Torre, B., Redfield, R. L., & Halegoua-DeMarzio, D. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-89408-z · Cited by 51
Rochoń, J., Kalinowski, P., Szymanek-Majchrzak, K., & Grąt, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i23.2964 · Cited by 44
“In a murine study of strepto- zotocin-and high-fat diet (HFD)-induced T2DM and NASH, liraglutide significantly ameliorated steatosis, inflammation, hepatocyte ballooning, and suppressed hepatocarcinogenesis[132].”
Hansen, H. H., Pors, S. E., Andersen, M. W., Vyberg, M., Nøhr-Meldgaard, J., Nielsen, M. H., Oró, D., Madsen, M. R., Lewińska, M., Møllerhøj, M. B., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-50328-5 · Cited by 42
“In agreement, GLP1R agonists have been reported to reduce hepatocarcinogenesis in non-obese chemical carcinogen-induced mouse models of HCC, perhaps by limiting liver pro-tumorigenic metabolic factors such as hepatic insulin resistance, steatosis and inflammation 90,91 .”
MASLD-Related HCC—Update on Pathogenesis and Current Treatment Options
Leyh, C., Coombes, J. D., Schmidt, H., Canbay, A. E., Manka, P. P., & Best, J. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14040370 · Cited by 43
“Impressively, in contrast to the control group, liraglutide completely suppressed the development of HCC and also significantly attenuated steatosis and inflammation [91].”
BackgroundMASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38
“Pre-clinical data suggest that GLP1-RAs may reduce the incidence of HCC associated with MASH by restoring the balance between adiponectin and leptin levels [307,326].”
Arvanitakis, K., Koufakis, T., Kotsa, K., & Germanidis, G. S. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106261 · Cited by 39
Type 2 Diabetes Mellitus and Liver Disease: Across the Gut–Liver Axis from Fibrosis to Cancer
Manilla, V., Santopaolo, F., Gasbarrini, A., & Ponziani, F. R. (2023) · Nutrients · doi:10.3390/nu15112521 · Cited by 39
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
Shabil, M., Khatib, M. N., Ballal, S., Bansal, P., Tomar, B. S., Ashraf, A., Kumar, M., Sinha, A., Rawat, P., Gaidhane, A. M., et al. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01775-2 · Cited by 34
Obesity Management in the Primary Prevention of Hepatocellular Carcinoma
Zunica, E. R. M., Heintz, E. C., Axelrod, C. L., & Kirwan, J. P. (2022) · Cancers · doi:10.3390/cancers14164051 · Cited by 32
Wang, Y., Fleishman, J. S., Li, T., Li, Y., Ren, Z., Chen, J., & Ding, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1336216 · Cited by 31
Orabi, D., Berger, N. A., & Brown, J. M. (2021) · Cancers · doi:10.3390/cancers13143473 · Cited by 27
“However, a number of studies have reported their presence in human hepatocytes and have demonstrated direct effects of GLP-1RAs on hepatocytes and HCC cell lines in vitro [187,190–194].”
BackgroundInfluentialChen, W., Ng, H.-J., Jao, A.-T., Wu, S., & Soong, R. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112407 · Cited by 21
Mahadevan, A., Vosooghi, A., Arora, J. S., Kumar, R. S., Singh, G., Tsai, K. K., & Quandt, Z. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf703 · Cited by 16
Lu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Yamada, N., Matsushima‐Nishiwaki, R., Kobayashi, K., Tachi, J., & Kozawa, O. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108851 · Cited by 16
Tsiampali, C., Vachliotis, I. D., Goulas, A., & Pοlyzos, S. A. (2024) · HORMONES · doi:10.1007/s42000-024-00541-2 · Cited by 13
“Kojima et al. similarly showed a beneficial effect of liraglutide on hepatic steatosis and inflammation and, interestingly, a potentially preventive effect against the progression of NAFLD-associated HCC [22].”
BackgroundInsulin resistance: mechanisms and therapeutic interventions
Yu, L., Qian, J., Li, X., Tian, M., Bai, X., Yang, J., Deng, R., Lu, C., He, X., Lü, A., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00408-5 · Cited by 14
Wawrzak-Pienkowska, K., Pienkowski, T., Golonko, A., Krupa, A., Warpechowski, M., Płoński, A. F., Mojsak, P., Daniluk, J., Dâbrowski, A., & Kurek, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178290 · Cited by 12
Deficiency of peroxisomal NUDT7 stimulates de novo lipogenesis in hepatocytes
Song, J., Baek, I., Park, S., Oh, J., Kim, D., Song, K., Kim, M. K., Lee, H. W., Jang, B. K., & Jin, E. (2022) · iScience · doi:10.1016/j.isci.2022.105135 · Cited by 11
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic
Suzuki, H., Fujiwara, N., Singal, A. G., Baumert, T. F., Chung, R. T., Kawaguchi, T., & Hoshida, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001227 · Cited by 18
GLP-1 signaling in tumor metabolism and immunity: mechanisms and strategies
Luo, Y., Xu, H., Zhao, Y., Yang, B., & Zhang, Y. (2025) · Food & Function · doi:10.1039/d5fo03273c · Cited by 10
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
Tsiampali, C., Papaioannidou, P., Goulas, A., & Pοlyzos, S. A. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2274536 · Cited by 10
Vachliotis, I. D., Valsamidis, I., & Pοlyzos, S. A. (2023) · Cancers · doi:10.3390/cancers15215306 · Cited by 15
“…studies are required to clarify any potential additive or synergistic effects of GLP-1RAs and ICIs, particularly in regard to NAFLD-associated HCC. Notably, monotherapy with liraglutide [108] or exenatide [109], another GLP-1RA, was shown to prevent the development of HCC in NASH mouse models.”
BackgroundDalbeni, A., Vicardi, M., Natola, L. A., Cattazzo, F., Auriemma, A., Lombardi, R., Cinque, F., Carbonare, L. D., Mantovani, A., & Sacerdoti, D. (2025) · Cancer Medicine · doi:10.1002/cam4.71434 · Cited by 8
Dosda, A., Fauchier, G., Sabbah, N., Fauchier, L., Lecomte, T., & Ducluzeau, P. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101734 · Cited by 7
Chemoprevention of hepatocellular carcinoma
Schwenk, S., & Kaplan, D. E. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000836 · Cited by 7
“[113] In a retrospective cohort study including 1,890,020 patients with T2DM, GLP1RAs were associated with a reduced risk of HCC when compared with use of insulin and sulfonylureas (HR of 0.20 [0.14 – 0.31] and 0.39 [0.21 – 0.69], respectively).”
InfluentialMisceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 7
Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma
Akl, M. G., & Widenmaier, S. B. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1089124 · Cited by 9
“In addition, TZDs and GLP1 receptor agonists have been shown to reduce hepatocarcinogenesis, cell proliferation and invasion in animal models and cancer cell lines (Yang et al., 2015; Li et al., 2019; Kojima et al., 2020).”
BackgroundGLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD
Jiang, H., & Zang, L. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128283153231226103218 · Cited by 7
Research Progress of Natural Products with the Activity of Anti-nonalcoholic Steatohepatitis
Wang, R., Mao, Y., Yu, C., Rong, Z., Wang, R., Wang, Y., Lv, L., Gao, Y., Wang, Z., & Zhang, H. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575306598240503054317 · Cited by 7
Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma
Oura, K., Morishita, A., Tani, J., & Masaki, T. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s392051 · Cited by 6
“Liraglutide prevents progression from NAFLD to HCC occurrence in mice with obesity and streptozotocin-induced diabetes.(36) Promising therapeutic approaches target adiposity, hepatitis, and fibrosis through multiple mechanisms of action, such as GLP-1, glucagon receptor, and glucose-dependent insulinotropic polypeptid…”
BackgroundRISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
Cavalcante, L. N., Dezan, M. G. F., Paz, C. L. D. S. L., & Lyra, A. D. (2022) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.202204000-93 · Cited by 26
Li, X., Fan, M., Huang, R., Wang, K., & Huang, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-03223-6 · Cited by 7
“Previous studies have demonstrated the significant role of GLP-1 receptor agonists in the occurrence, development, and metastasis of various tumor cells [7, 8].”
Lin, J., Ren, T., Zhao, Q., Tong, Q., Liu, J., Ye, K., & Yuan, Y. (2025) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-025-03899-3 · Cited by 6
Zhan, K., Yang, X., Li, S., & Bai, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1270774 · Cited by 4
Wang, X., Lu, G., Zhou, Y., & Zhao, G. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02891-7 · Cited by 4
“…mechanisms involving systemic metabolic improvement and hepatic pathway modulation observed in the model (including lipid handling, inflammatory signaling, and cAMP–PKA– STAT3–related readouts), while the extent of direct hepa - tocyte target engagement remains to be validated in human liver [134].”
Beyene, E., Chirumamilla, L. G., Bisrat, M., Bowen, A., Fetle, Y., Wilkerson, B., Wudeneh, A. T., Gillani, S. F., Larbi, D. A., & Michael, M. B. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102760 · Cited by 2
Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk?
Renehan, A. G., & Pollak, M. (2026) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-26-0018 · Cited by 2
Mahalingam, S., Kharbanda, K. K., Casey, C. A., & Rasineni, K. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1752204 · Cited by 3
“Recognizing that chronic inflammation is a major driver of SLD progression and hepatocarcinogenesis, GLP-1 RAs demonstrate potent anti-inflammatory and tumor-suppressive actions (Que et al., 2019; Wan and Sun, 2019; Kojima et al., 2020; Zhao et al., 2014).”
Crecca, E., Giuseppe, G. D., Camplone, C., Benedetti, V. V., Melaiu, O., Mezza, T., Cencioni, C., & Spallotta, F. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108847 · Cited by 2
The effects of incretins as a double-edged sword on cancer
Mavaddat, H., Fouladi, A., Peyrovinasab, A., Khayatan, I., Targhi, H. J., Fakhri, M., Andarzbakhsh, K., Büsselberg, D., Razavi, S. M., & Rezazadeh, A. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11062-5 · Cited by 2
“Despite the reduction of steatosis, fat deposition, ballooning score, and inflammation, liver fibrosis was attenuated in Liraglutide therapy [70].”
Best, J., Kälsch, J., Krawczyk, M. J., Manka, P. P., Canbay, A. E., Schmidt, H., & Jochheim, L. S. (2025) · Die Gastroenterologie · doi:10.1007/s11377-025-00878-z · Cited by 1
Phillips, R., Ma, Y. T., Hanif, W., Shah, T., & Sivakumar, S. (2025) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2025.00303 · Cited by 3
Ma, J., Chen, K., Zhang, X., Lou, Y., Bai, Y., Wong, Y., Zheng, L., Li, L., Hu, Y., Li, Z., et al. (2025) · Biomaterials Research · doi:10.34133/bmr.0246 · Cited by 1
Nonoperative Management of Hepatic Adenomas: A Review
Garbarine, I. C., & Cloyd, J. M. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01406-0 · Cited by 1
Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists
Rashid, Z., Woldesenbet, S., Khalil, M., Altaf, A., Zindani, S., Mevawalla, A., Sarfraz, A., Mumtaz, K., & Pawlik, T. M. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10300-1 · Cited by 1
Lou, Q., Cai, J., & Yin, J. (2026) · Microorganisms · doi:10.3390/microorganisms14040853 · Cited by 1
“Preclinical data suggest that the hepatoprotective effects of GLP-1RAs are most pronounced in the early stages of fibrosis [83,84].”
Chen, S. T., Donisan, T., Lewis, B. R., Kailash, V., Herrmann, S. M., Ruddy, K. J., Cheung, D. Y. C., Desautels, D. N., Jassal, D. S., & Herrmann, J. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag109 · Cited by 1
“39–43 For instance, GLP-1 RAs have been shown to inhibit the growth and induce apoptosis of breast cancer cells via increase in cAMP levels and activity, even though these cancer cells lack classic GLP-1 receptors.”
Vozza, A., Biagi, F., Chiara, R., Vizzutti, F., & Marra, F. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04456-1 · Cited by 1
“Moreover, in a diabetic murine MASH-HCC model, GLP-1R agonist treatment prevented tumor progression and reduced hepatic cytokine expression [80].”
Chemoprevention in hepatocellular carcinoma
Suzuki, H., Ng, C. H., Tan, D. J. H., Teng, M. L. P., Kawaguchi, T., & Huang, D. Q. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00614-7 · Cited by 1
Molecular Mechanisms, Diagnosis and Treatments in Digestive Malignancy
Kanda, T., Masuzaki, R., Sasaki, R., Kogure, H., & Moriyama, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076471 · Cited by 1
“Kojima et al. demonstrated that GLP1 agonists prevented the progression of HCC in a mouse model of NASH [7].”
BackgroundVijayakumar, V., Gaba, R. C., Huang, Y.-H., Davis, I., Roman, R., Guzman, G., Lokken, R. P., & Schachtschneider, K. M. (2024) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2024.01.029
Hu, M., Jiang, C.-J., & Yi, C. (2026) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2026.13178
“A preclinical study demonstrated that liraglutide and exenatide suppress HCC cell proliferation and induce autophagy.”
InfluentialNoma, T., Li, Y., Wada, Y., Morine, Y., Ikemoto, T., Saito, Y., Shimada, M., & Goel, A. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01584-x
“Morerecently,accumulatingevidencehassuggestedthatGLP-1RAsmay exert antitumor effects through modulation of cellular metabolism, suppression of proliferation, and induction of apoptosis in multiple cancer types, including HCC 45 – 50 .”
Zhou, M., Zhou, P., Xu, W., Zhu, D., Zhang, F., Li, W., & Ye, C. (2026) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s611091
“32 A retrospective cohort study conducted in Hong Kong involving 62,699 T2DM patients showed that, SGLT-2is use was associated with a lower risk of HCC compared with DPP-4is use.”
Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8391-3
Xie, Y., Zhang, X., & Chen, B. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1913929
“Preclinical studies suggest effects on STAT3-related signaling and NASH-associated hepatocarcinogenesis (27, 28), while meta-analyses have risk (29, 30, 63).”
GLP-1 RECEPTOR AGONISTS IN HUMAN CANCERS: A NARRATIVE LITERATURE REVIEW
Rizopoulos, T. (2026) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2026.31.3.2484
Type 2 diabetes medications and their implications for cancer treatment: A comprehensive review
Shakour, N., Hosseini, F., Esmaeili, Z., & Hadizadeh, F. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101521
Metadata
- Authors
- Kojima, M., Takahashi, H., Kuwashiro, T., Tanaka, K., Mori, H., Ozaki, I., Kitajima, Y., Matsuda, Y., Ashida, K., Eguchi, Y., & Anzai, K.
- Affiliations
- Saga University (JP)
- Kyushu University (JP)
- Kurume University (JP)
- Corresponding author
- Anzai, Keizo
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-08-10
- Volume
- 21
- Issue
- 16
- Pages
- 5722
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7460814
- OpenAlex
- W3047956076
- Cited by
- 69
- References
- 58
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 14 · 2023: 12 · 2022: 10 · 2021: 3
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, liraglutide, nonalcoholic steatohepatitis, hepatocellular carcinoma, hepatocarcinogenesis, diabetes mellitus, streptozotocin-induced diabetes, high-fat diet, hepatic steatosis, liver inflammation, hepatocyte ballooning, insulin, pancreatic beta cells, glycemic control
- MeSH terms
- Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Blood Glucose, Diabetes Mellitus, Experimental, Disease Models, Animal, Carcinoma, Hepatocellular, Hypoglycemic Agents, Insulin, Liver Neoplasms, Male, Mice, Inbred C57BL, Streptozocin, Treatment Outcome, Mice, Diet, High-Fat, Carcinogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.